Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 6, 2006

View Archived Issues

Stem cell transfer reduces infarct size in ST-segment elevation myocardial infarction

T cells armed with bispecific antibodies investigated in cancer

Schering-Plough presents Q4 highlights

Acceptance of trastuzumab-DM1 IND triggers milestone to ImmunoGen

Grant supports DeveloGen's development of beta-cell regeneration drugs

Optimization of route and schedule of IC-41 for hepatitis C

New attenuated ETEC vaccine completes phase I study

IDM Pharma closes enrollment in phase II EP-2101 therapeutic vaccine trial

New phase II study investigates PDX-101 for T-cell lymphomas

The phytochemical beta-cryptoxanthin prevents bone loss in animal model

BTG licenses amyloid-induced toxicity inhibitors to Senexis

Nuvigil NDA action date extended by three months

ARQ-197 begins phase I study in cancer patients

Apoxis receives orphan drug designation for APO-200

Nabi updates progress with Civacir

CS-917 studied in phase IIb trial for type 2 diabetes

Phase I study for AB-1001 transdermal patch in CINV

Fast track designation for rifalazil in peripheral arterial disease

First phase III trial for EUR-1008M in patients with pancreatic insufficiency

Teva announces final results of merger consideration for Ivax acquisition

Compassionate use IND approved for Davanat/5-FU in cholangiocarcinoma

New trial investigates Ad2/HIF-1alpha/VP16 for intermittent claudication

Nicotine addiction vaccine surpasses target antibody level in dose-optimization study

Efficacy shown for ISTA's tobramycin / prednisolone acetate combination product

Intravenous Keppra receives European positive opinion, FDA approvable letter

Macugen approved in Europe for wet AMD

Approval for new formulation of Imitrex Injection

New treatments for cancer covered in recent patents

Recently reported novel agents for obesity and lipoprotein disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...